The pharmaceutical company AstraZeneca announced on Sunday that it had conducted a study of the people who were vaccinated against COVID-19, which did not show any increased risk of blood clots after its use, Reuters reported, BTA reported.
The study was carried out on 17 million people vaccinated in the European Union and the United Kingdom. A careful study of all available safety data in over 17 million people vaccinated in the European Union and the United Kingdom with the AstraZeneca vaccine against COVID-19 showed no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia. in any of the specified age groups, gender, account or in any particular country, “the company said in a statement.
Authorities in Denmark, Norway and Iceland have stopped using the vaccine due to suspicions of blood clots, and Austria stopped using a certain batch last week while an investigation into deaths due to coagulation disorders is underway. On Sunday, Ireland suspended the AstraZeneca vaccine as a “precautionary measure”.
The pharmaceutical company announced that additional tests were being carried out by it and the European health authorities, and none of the repeated tests showed any cause for concern. There are no confirmed problems with any of the vaccine batches in Europe and the rest of the world, the company said. On Friday, Bulgaria also stopped using the AstraZeneca vaccine until the causes of death after its administration were clarified.
–
